{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T18:28:36Z","timestamp":1785176916938,"version":"3.55.0"},"reference-count":153,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.4065\/mcp.2011.0514","type":"journal-article","created":{"date-parts":[[2011,12,3]],"date-time":"2011-12-03T04:27:38Z","timestamp":1322886458000},"page":"1230-1243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Current Concepts in Antimicrobial Therapy Against Select Gram-Positive Organisms: Methicillin-ResistantStaphylococcus aureus, Penicillin-Resistant Pneumococci, and Vancomycin-Resistant Enterococci"],"prefix":"10.4065","volume":"86","author":[{"given":"Ana Maria","family":"Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen W.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.4065\/mcp.2011.0514_bib1","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1086\/533590","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus","volume":"46","author":"Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/499815","article-title":"Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care\u2013associated blood stream infections","volume":"42","author":"Seybold","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/INF.0b013e31815819bb","article-title":"A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections","volume":"27","author":"Gorwitz","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.4065\/mcp.2011.0514_bib5","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/archderm.135.12.1566","article-title":"Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus\u2014Minnesota and North Dakota, 1997-1999","volume":"135","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","journal-title":"Arch Dermatol"},{"issue":"9308","key":"10.4065\/mcp.2011.0514_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(02)07877-7","article-title":"Association between Staphylococcus aureus strains carrying gene for panton-valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients","volume":"359","author":"Gillet","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1086\/427148","article-title":"Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the panton-valentine leukocidin genes","volume":"40","author":"Francis","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.4065\/mcp.2011.0514_bib8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa043252","article-title":"Methicillin-resistant Staphylococcus aureus disease in three communities","volume":"352","author":"Fridkin","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/520655","article-title":"Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus","volume":"45","author":"Boucher","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib11","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcp070747","article-title":"Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus [published correction appears in N Engl J Med. 2007;357(13):1357 dosage error in text]","volume":"357","author":"Daum","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.4065\/mcp.2011.0514_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/510681","article-title":"Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus","volume":"44","author":"Cook","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/ciq067","article-title":"Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA-its evolving antimicrobial resistance and implications for therapy","volume":"52","author":"Chua","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1473-3099(10)70053-0","article-title":"Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in Europe","volume":"10","author":"Otter","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"9725","key":"10.4065\/mcp.2011.0514_bib17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0140-6736(09)61999-1","article-title":"Community-associated methicillin-resistant Staphylococcus aureus","volume":"375","author":"Deleo","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.4065\/mcp.2011.0514_bib18","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States","volume":"298","author":"Klevens","year":"2007","journal-title":"JAMA"},{"issue":"12","key":"10.4065\/mcp.2011.0514_bib19","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1086\/509506","article-title":"Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?","volume":"194","author":"Voyich","year":"2006","journal-title":"J Infect Dis"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1086\/377501","article-title":"Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro","volume":"37","author":"Siberry","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.4065\/mcp.2011.0514_bib22","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/529445","article-title":"Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Moellering","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"suppl 4","key":"10.4065\/mcp.2011.0514_bib24","first-page":"iv53","article-title":"CANVAS 2: The second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.mib.2009.08.001","article-title":"The clinical consequences of antimicrobial resistance","volume":"12","author":"Rice","year":"2009","journal-title":"Curr Opin Microbiol"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib27","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 5","key":"10.4065\/mcp.2011.0514_bib28","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1086\/533592","article-title":"Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains","volume":"46","author":"Sakoulas","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001\u201305","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib30","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.00582-08","article-title":"Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)","volume":"46","author":"Rybak","year":"2008","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib31","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jac\/dkn372","article-title":"Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates","volume":"62","author":"Rehm","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib32","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","article-title":"The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus","volume":"44","author":"Tenover","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib33","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/00003495-200969060-00004","article-title":"Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management","volume":"69","author":"Patel","year":"2009","journal-title":"Drugs"},{"issue":"8","key":"10.4065\/mcp.2011.0514_bib35","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1128\/AAC.01365-08","article-title":"Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA","volume":"53","author":"Horne","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/infdis\/jir275","article-title":"Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet [editorial]?","volume":"204","author":"Holland","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib37","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/jir270","article-title":"Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations","volume":"204","author":"Holmes","year":"2011","journal-title":"J Infect Dis"},{"issue":"suppl 3","key":"10.4065\/mcp.2011.0514_bib38","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1086\/519470","article-title":"Limitations of vancomycin in the management of resistant Staphylococcal infections","volume":"45","author":"Kollef","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.4065\/mcp.2011.0514_bib39","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib40","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin Ther"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7164\/antibiotics.31.170","article-title":"Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. SP. II: extraction and chemical characterization","volume":"31","author":"Bardone","year":"1978","journal-title":"J Antibiot (Tokyo)"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0514_bib42","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1086\/491711","article-title":"Vancomycin resistance in gram-positive cocci","volume":"42","author":"Courvalin","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/jac\/dkp065","article-title":"Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom","volume":"63","author":"Gould","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib44","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib45","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00134-003-2088-1","article-title":"Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin","volume":"30","author":"Kollef","year":"2004","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/38.5.865","article-title":"Penetration of vancomycin into human lung tissue","volume":"38","author":"Cruciani","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib47","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkg262","article-title":"Intrapulmonary penetration of linezolid","volume":"51","author":"Honeybourne","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.4065\/mcp.2011.0514_bib48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.CCM.0000168206.59873.80","article-title":"Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib49","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.4065\/mcp.2011.0514_bib51","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1086\/503839","article-title":"Serotonin toxicity associated with the use of linezolid: a review of postmarketing data","volume":"42","author":"Lawrence","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib52","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1086\/504809","article-title":"Linezolid and serotonergic drug interactions: a retrospective survey","volume":"43","author":"Taylor","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib53","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2006.04.017","article-title":"High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency","volume":"28","author":"Lin","year":"2006","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.4065\/mcp.2011.0514_bib54","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1086\/430441","article-title":"Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?","volume":"40","author":"Palenzuela","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.4065\/mcp.2011.0514_bib55","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1086\/379012","article-title":"Linezolid-associated toxic optic neuropathy: a report of 2 cases","volume":"37","author":"Lee","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.diagmicrobio.2009.10.011","article-title":"Linezolid surveillance program results for 2008 (LEADER program for 2008)","volume":"65","author":"Farrell","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9277","key":"10.4065\/mcp.2011.0514_bib57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib58","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/650574","article-title":"Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus","volume":"50","author":"Morales","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"suppl 5","key":"10.4065\/mcp.2011.0514_bib59","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1086\/533595","article-title":"Management of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Cosgrove","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.4065\/mcp.2011.0514_bib60","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1128\/AAC.47.8.2682-2684.2003","article-title":"In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis","volume":"47","author":"Laganas","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib61","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","article-title":"Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus","volume":"50","author":"Cui","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib62","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1128\/JCM.44.2.655-656.2006","article-title":"Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin","volume":"44","author":"Skiest","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.4065\/mcp.2011.0514_bib63","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.4065\/mcp.2011.0514_bib64","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.4065\/mcp.2011.0514_bib65","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1086\/533441","article-title":"Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia","volume":"46","author":"Pertel","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib66","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jinf.2006.11.006","article-title":"Eosinophilic pneumonia induced by daptomycin","volume":"54","author":"Hayes","year":"2007","journal-title":"J Infect"},{"issue":"11","key":"10.4065\/mcp.2011.0514_bib67","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1086\/652656","article-title":"Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases","volume":"50","author":"Miller","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib68","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycyl-amido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.4065\/mcp.2011.0514_bib69","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.26.8.1099","article-title":"Tigecycline: first of a new class of antimicrobial agents","volume":"26","author":"Rose","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib70","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1086\/505494","article-title":"Tigecycline: a critical analysis","volume":"43","author":"Stein","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib71","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkl403","article-title":"Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose","volume":"58","author":"Rodvold","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 5","key":"10.4065\/mcp.2011.0514_bib72","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline","volume":"41","author":"Meagher","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.4065\/mcp.2011.0514_bib73","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","article-title":"Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam","volume":"49","author":"Breedt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib74","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","article-title":"Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia","volume":"68","author":"Freire","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib75","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/jac\/dkq454","article-title":"Tigecycline for severe infections: the gap between the warning and the necessity","volume":"66","author":"Curcio","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib77","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/46.5.775","article-title":"Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin\u2013dalfopristin in patients intolerant of or failing prior therapy","volume":"46","author":"Drew","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib78","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/318702","article-title":"Arthralgias and myalgias related to quinupristin-dalfopristin administration","volume":"32","author":"Olsen","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib79","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1586\/14787210.4.5.743","article-title":"Telavancin: a new lipoglycopeptide with multiple mechanisms of action","volume":"4","author":"Kanafani","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"12","key":"10.4065\/mcp.2011.0514_bib80","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.4065\/mcp.2011.0514_bib81","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/429914","article-title":"Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria","volume":"40","author":"Stryjewski","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib82","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","article-title":"Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects","volume":"49","author":"Shaw","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0514_bib83","first-page":"127","article-title":"Role of telavancin in treatment of skin and skin structure infections","volume":"3","author":"Bonkowski","year":"2010","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib84","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","article-title":"Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study","volume":"50","author":"Stryjewski","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib85","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1128\/AAC.01242-06","article-title":"In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model","volume":"51","author":"Jacqueline","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib86","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00149-08","article-title":"In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States","volume":"52","author":"Ge","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0514_bib87","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0163-4453(09)60010-4","article-title":"Future gazing in the management of multiply drug-resistant gram-positive infection","volume":"59","author":"Wilcox","year":"2009","journal-title":"J Infect"},{"issue":"7","key":"10.4065\/mcp.2011.0514_bib88","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline","volume":"69","author":"Zhanel","year":"2009","journal-title":"Drugs"},{"issue":"suppl 4","key":"10.4065\/mcp.2011.0514_bib89","first-page":"iv9","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-gram-positive activity","volume":"65","author":"Biek","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.4065\/mcp.2011.0514_bib90","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib91","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/clinids\/14.4.801","article-title":"Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment","volume":"14","author":"Musher","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib92","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1086\/377534","article-title":"An international prospective study of Pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome","volume":"37","author":"Yu","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0514_bib93","series-title":"Transplant Infections","author":"Bowden","year":"2010"},{"issue":"11","key":"10.4065\/mcp.2011.0514_bib94","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1086\/598975","article-title":"Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance","volume":"48","author":"Weinstein","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/mdr.2010.0129","article-title":"Impact of new clinical laboratory standards institute Streptococcus pneumoniae penicillin susceptibility testing breakpoints on reported resistance changes over time","volume":"17","author":"Mera","year":"2011","journal-title":"Microb Drug Resist"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib96","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/infdis\/164.2.313","article-title":"Antigenic variation of penicillin-binding proteins from penicillin-resistant clinical strains of Streptococcus pneumoniae","volume":"164","author":"Hakenbeck","year":"1991","journal-title":"J Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib97","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1128\/AAC.46.1.125-131.2002","article-title":"Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae","volume":"46","author":"Canu","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.4065\/mcp.2011.0514_bib98","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1128\/JCM.43.12.6035-6041.2005","article-title":"Relationship between the original multiply resistant South African isolates of Streptococcus pneumoniae from 1977 to 1978 and contemporary international resistant clones","volume":"43","author":"Reinert","year":"2005","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib99","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/mdr.2009.0056","article-title":"The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics","volume":"15","author":"Mera","year":"2009","journal-title":"Microb Drug Resist"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib100","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.mcna.2006.07.007","article-title":"Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus","volume":"90","author":"Cunha","year":"2006","journal-title":"Med Clin North Am"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib101","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.4065\/mcp.2011.0514_bib102","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1473-3099(02)00316-X","article-title":"Treatment of drug-resistant pneumococcal pneumonia","volume":"2","author":"Garau","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib103","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1086\/430829","article-title":"A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance","volume":"41","author":"Fuller","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"10.4065\/mcp.2011.0514_bib104","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"10.4065\/mcp.2011.0514_bib105","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/428055","article-title":"Antimicrobial safety: focus on fluoroquinolones","volume":"41","author":"Owens","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"suppl 4","key":"10.4065\/mcp.2011.0514_bib106","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1086\/382709","article-title":"Quinolone resistance mechanisms in pneumococci","volume":"38","author":"Eliopoulos","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib107","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2334-11-66","article-title":"Severe pneumococcal pneumonia: impact of new quinolones on prognosis","volume":"11","author":"Olive","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib108","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other \u03b2-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib109","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.4065\/mcp.2011.0514_bib110","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1128\/AAC.46.5.1345-1351.2002","article-title":"Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia","volume":"46","author":"Gentry-Nielsen","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0514_bib111","unstructured":"Cammarata SK, San Pedro GS, Timm JA, et al. Comparison of linezolid versus ceftriaxone\/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia [abstract]. In: Abstracts of the European Congress of Clinical Microbiology and Infectious Diseases. Stockholm, Sweden: 2000."},{"issue":"7","key":"10.4065\/mcp.2011.0514_bib112","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1128\/AAC.01398-07","article-title":"In vitro activity of telavancin against resistant gram-positive bacteria","volume":"52","author":"Krause","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib113","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/AAC.50.2.770-773.2006","article-title":"Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters","volume":"50","author":"Stucki","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2005.05.004","article-title":"Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.4065\/mcp.2011.0514_bib115","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard\u2013Eighth Edition","author":"Clinical and Laboratory Standards Institute","year":"2009"},{"issue":"8575","key":"10.4065\/mcp.2011.0514_bib116","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(88)91037-9","article-title":"Vancomycin-resistant enterococci","volume":"1","author":"Uttley","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib117","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib118","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/523588","article-title":"Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia","volume":"46","author":"Erlandson","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib119","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1592\/phco.26.3.347","article-title":"Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients","volume":"26","author":"Segreti","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/515605","article-title":"Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of \u03b2-lactam resistance","volume":"178","author":"Rybkine","year":"1998","journal-title":"J Infect Dis"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib121","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1128\/AAC.37.9.1966","article-title":"Genes involved in the regulation of \u03b2-lactamase production in enterococci and staphylococci","volume":"37","author":"Zscheck","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib122","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1574-6968.1992.tb05089.x","article-title":"Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus","volume":"93","author":"Noble","year":"1992","journal-title":"FEMS Microbiol Lett"},{"issue":"8","key":"10.4065\/mcp.2011.0514_bib123","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/AAC.37.8.1563","article-title":"Genetics and mechanisms of glycopeptide resistance in enterococci","volume":"37","author":"Arthur","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib124","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.diagmicrobio.2006.12.022","article-title":"Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program","volume":"58","author":"Deshpande","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"10.4065\/mcp.2011.0514_bib125","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/archinte.158.10.1127","article-title":"The role of \u201ccolonization pressure\u201d in the spread of vancomycin-resistant enterococci: an important infection control variable","volume":"158","author":"Bonten","year":"1998","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib126","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/0003-4819-135-3-200108070-00009","article-title":"The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 US adult intensive care units","volume":"135","author":"Fridkin","year":"2001","journal-title":"Ann Intern Med"},{"issue":"suppl 4","key":"10.4065\/mcp.2011.0514_bib127","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/382690","article-title":"\u201cCollateral damage\u201d from cephalosporin or quinolone antibiotic therapy","volume":"38","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.4065\/mcp.2011.0514_bib128","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJM200105103441903","article-title":"Control of vancomycin-resistant Enterococcus in health care facilities in a region","volume":"344","author":"Ostrowsky","year":"2001","journal-title":"N Engl J Med"},{"issue":"19","key":"10.4065\/mcp.2011.0514_bib129","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJM199611073351907","article-title":"Antimicrobial-drug resistance","volume":"335","author":"Gold","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1086\/321815","article-title":"Vancomycin-resistant enterococci: mechanisms and clinical observations","volume":"33","author":"Gold","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib131","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003495-200262030-00002","article-title":"Treatment options for vancomycin-resistant enterococcal infections","volume":"62","author":"Linden","year":"2002","journal-title":"Drugs"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib132","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jac\/40.1.144","article-title":"Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant Enterococcus","volume":"40","author":"Howe","year":"1997","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib133","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0732-8893(98)00148-5","article-title":"Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen","volume":"33","author":"Linden","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib134","first-page":"999","article-title":"Bacteriologic efficacy of nitrofurantoin for urinary tract infection due to vancomycin-resistant Enterococcus faecium [abstract 208]","volume":"29","author":"Linden","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11908-010-0138-8","article-title":"Treatment of resistant enterococcal urinary tract infections","volume":"12","author":"Swaminathan","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"10.4065\/mcp.2011.0514_bib136","series-title":"Treatment of Infective Endocarditis","first-page":"81","article-title":"Antimicrobial susceptibility of enterococci: in vitro studies of the action of antibiotics alone and in combination","author":"Moellering","year":"1981"},{"issue":"901","key":"10.4065\/mcp.2011.0514_bib137","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.166.3901.122","article-title":"Phosphonomycin, a new antibiotic produced by strains of Streptomyces","volume":"166","author":"Hendlin","year":"1969","journal-title":"Science"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib138","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jac\/35.1.228","article-title":"Antibacterial spectrum of fosfomycin trometamol","volume":"35","author":"Barry","year":"1995","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib139","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s101560200004","article-title":"Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay","volume":"8","author":"Okazaki","year":"2002","journal-title":"J Infect Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2009.03.009","article-title":"Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: a systematic review of microbiological, animal and clinical studies","volume":"34","author":"Falagas","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.4065\/mcp.2011.0514_bib141","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0732-8893(98)80002-3","article-title":"Antimicrobial activity of quinupristin-dalfopristin (RP 59500, synercid\u00ae) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada","volume":"31","author":"Jones","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib142","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jac\/44.2.251","article-title":"The efficacy and safety of quinupristin\/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium","volume":"44","author":"Moellering","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib143","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.4065\/mcp.2011.0514_bib144","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/319986","article-title":"Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid","volume":"32","author":"Babcock","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib145","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and-resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.4065\/mcp.2011.0514_bib146","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1128\/AAC.49.12.5166-5168.2005","article-title":"In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin","volume":"49","author":"Pankey","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.4065\/mcp.2011.0514_bib147","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jinf.2006.11.007","article-title":"Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients","volume":"54","author":"Poutsiaka","year":"2007","journal-title":"J Infect"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib148","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0514_bib149","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkn250","article-title":"Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study","volume":"62","author":"Florescu","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials","volume":"50","author":"Gardiner","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.4065\/mcp.2011.0514_bib151","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/jac\/dkl007","article-title":"Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis","volume":"57","author":"Gerber","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0514_bib152","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1128\/AAC.48.2.670-672.2004","article-title":"Penetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administration","volume":"48","author":"V\u00e1zquez","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.4065\/mcp.2011.0514_bib153","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1128\/AAC.00051-06","article-title":"Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients","volume":"50","author":"Myrianthefs","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.4065\/mcp.2011.0514_bib154","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1468-1331.2005.01001.x","article-title":"Clinical experience with linezolid for the treatment of central nervous system infections","volume":"12","author":"Rupprecht","year":"2005","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.4065\/mcp.2011.0514_bib155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s15010-007-7171-z","article-title":"Linezolid in postneurosurgical infections","volume":"36","author":"Maure","year":"2008","journal-title":"Infection"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611652610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611652610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:33:48Z","timestamp":1675902828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611652610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":153,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0025619611652610"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2011.0514","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Concepts in Antimicrobial Therapy Against Select Gram-Positive Organisms: Methicillin-ResistantStaphylococcus aureus, Penicillin-Resistant Pneumococci, and Vancomycin-Resistant Enterococci","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2011.0514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}